Caris Life Sciences Inc - Class A

Research Caris Life Sciences Inc - Class A (CAI) on Bullrun: market cap USD 7.92B, P/E 75.2. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 7.92B; P/E is 75.2.

Peer valuation comparison

Latest P/E is 75.24x versus a Healthcare sector median of 24.46x (207.6% above).

Latest P/E is 75.24x versus a United States median of 24.87x (202.6% above).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 812.03M-USD 68.09MUSD 66.90M66.4%-3.22USD 796.27MUSD 378.99MUSD 577.31M
FY2024USD 412.26M-USD 281.89M-USD 253.64Mn/a-10.66USD 63.95MUSD 379.53M-USD 2.50B
FY2023USD 306.13M-USD 341.42M-USD 298.42Mn/a-13.24n/an/a-USD 2.14B

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 7.92B75.2n/an/a
20252025-12-31USD 7.61Bn/an/an/a

About Caris Life Sciences Inc - Class A

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Caris Life Sciences Inc - Class A's market cap?

Caris Life Sciences Inc - Class A's market capitalization is USD 7.92B.

What is Caris Life Sciences Inc - Class A's P/E ratio?

Caris Life Sciences Inc - Class A's price-to-earnings (P/E) ratio is 75.2.

What does Caris Life Sciences Inc - Class A do?

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms.